ReviewDiabetes, obesity & metabolism2025
A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on Canada.
Review in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on Canada.Diabetes, obesity & metabolism · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cardiometabolic disease (CMD) is associated with an increased risk of metabolic dysfunction-associated steatohepatitis (MASH). Most patients develop MASH in association with type 2 diabetes and obesity. Optimal disease management requires effective multidisciplinary collaboration between primary care physicians and specialists from different medical fields; however, awareness of the risks, association with CMD, diagnosis, complications, and management strategies of MASH is low among non-liver specialists. In Canada, variable access to diagnostic testing and, until recently, the lack of national MASH guidelines, are also barriers to effective disease management. Ongoing cross-disciplinary education and wide systemic changes are required to ensure timely patient identification and the establishment of holistic patient care pathways that can begin to address MASH and associated CMD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.